Do Xanthine Oxidase Inhibitors (XOI) have clinically useful anti-ischaemic effects in the treatment of angina pectoris? A double-blind, placebo controlled trial
Completed
- Conditions
- Coronary Artery Disease - patients with chronic stable anginaCirculatory SystemCoronary Artery Disease
- Registration Number
- ISRCTN82040078
- Lead Sponsor
- niversity of Dundee (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
1. Documented Coronary artery Disease (CAD) on angiography
2. Chronic stable angina (greater than two months)
3. Able to do Exercise Treadmill Test (ETT)
4. Aged between 30 and 85 years
Exclusion Criteria
1. Contra-indication or unable to do ETT
2. Already on allopurinol or previous allergy to allopurinol
3. Left Ventricular (LV) ejection fraction less than 45%
4. Myocardial Infarction (MI) or Acute Coronary Syndrome (ACS) over the last two months
5. Change to anti-anginal therapy over the last month
6. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft (CABG) within the last six months
7. Significant renal or hepatic impairment
8. On medication that may interact with allopurinol (e.g., warfarin)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to ST depression on ETT.<br><br>Outcomes will be assessed at the start and every six weeks (at the end of each treatment period - allopurinol or placebo).
- Secondary Outcome Measures
Name Time Method 1. Total exercise time<br>2. Time to symptom on ETT<br>3. Assessment of angina<br>4. Measurement of C-Reactive Protein (CRP), B-type Natriuretic Peptide (BNP) and Procollagen III N-terminal Peptide (PIIINP)<br><br>Outcomes will be assessed at the start and every six weeks (at the end of each treatment period - allopurinol or placebo).